IN VITRO–IN VIVO SCALE-UP OF DRUG TRANSPORT ACTIVITIES - Drug Transporters: Molecular Characterization and Role in Drug Disposition - page 583

major full-length isoform of the liver-specific transporter-1 (rlst-1) in rat liver. FEBS Lett
474, 242-245.
19. Hirano, M., Maeda, K., Shitara, Y. and Sugiyama, Y. (2006). Drug-drug interaction be-
tween pitavastatin and various drugs via OATP1B1. Drug Metab Dispos 34, 1229-1236.
20. Shimizu, M., Fuse, K., Okudaira, K., Nishigaki, R., Maeda, K., Kusuhara, H. and Sugiyama,
Y. (2005). Contribution of OATP (organic anion-transporting polypeptide) family trans-
porters to the hepatic uptake of fexofenadine in humans. Drug Metab Dispos 33, 1477-
1481.
21. Ishiguro, N., Maeda, K., Kishimoto, W., Saito, A., Harada, A., Ebner, T., Roth, W., Igarashi,
T. and Sugiyama, Y. (2006). Predominant contribution of OATP1B3 to the hepatic uptake
of telmisartan, an angiotensin II receptor antagonist, in humans. Drug Metab Dispos 34,
1109-1115.
22. Yamashiro, W., Maeda, K., Hirouchi, M., Adachi, Y., Hu, Z. and Sugiyama, Y. (2006).
Involvement of transporters in the hepatic uptake and biliary excretion of valsartan, a
selective antagonist of the angiotensin II AT1-receptor, in humans. Drug Metab Dispos 34,
1247-1254.
23. Hagenbuch, B., Scharschmidt, B.F. and Meier, P.J. (1996). Effect of antisense oligonu-
cleotides on the expression of hepatocellular bile acid and organic anion uptake systems
in Xenopus laevis oocytes. Biochem J 316(Pt 3), 901-904.
24. Nakai, D., Nakagomi, R., Furuta, Y., Tokui, T., Abe, T., Ikeda, T. and Nishimura, K. (2001).
Human liver-specific organic anion transporter, LST-1, mediates uptake of pravastatin by
human hepatocytes. J Pharmacol Exp Ther 297, 861-867.
25. Takagi, M., Morita, K., Nakai, D., Nakagomi, R., Tokui, T. and Koizumi, M. (2004).
Enhancement of the inhibitory activity of oatp antisense oligonucleotides by incorporation
of 2 - O ,4 - C -ethylene-bridged nucleic acids (ENA) without a loss of subtype selectivity.
Biochemistry 43, 4501-4510.
26. Materna, V., Stege, A., Surowiak, P., Priebsch, A. and Lage, H. (2006). RNA interference-
triggered reversal of ABCC2-dependent cisplatin resistance in human cancer cells.
Biochem Biophys Res Commun 348, 153-157.
27. Nieth, C., Priebsch, A., Stege, A. and Lage, H. (2003). Modulation of the classical mul-
tidrug resistance (MDR) phenotype by RNA interference (RNAi). FEBS Lett 545, 144-
150.
28. Aoki, J., Suzuki, H. and Sugiyama, Y. (2000). Quantitative prediction of in vivo biliary
excretion clearance across the bile canalicular membrane from in vitro transport studies
with isolated membrane vesicles. In: Proceedings of the Millennial World Congress of
Pharmaceutical Sciences , April 16-20, San Francisco, CA, p. 92.
29. Ghibellini, G., Leslie, E.M. and Brouwer, K.L. (2006). Methods to evaluate biliary excre-
tion of drugs in humans: an updated review. Mol Pharmacol 3, 198-211.
30. Niinuma, K., Kato, Y., Suzuki, H., Tyson, C.A., Weizer, V., Dabbs, J.E., Froehlich, R.,
Green, C.E. and Sugiyama, Y. (1999). Primary active transport of organic anions on bile
canalicular membrane in humans. Am J Physiol 276, G1153-G1164.
31. Shilling, A.D., Azam, F., Kao, J. and Leung, L. (2006). Use of canalicular membrane
vesicles (CMVs) from rats, dogs, monkeys and humans to assess drug transport across the
canalicular membrane. J Pharmacol Toxicol Methods 53, 186-197.
32. Allen, J.D., van Loevezijn, A., Lakhai, J.M., van der Valk, M., van Tellingen, O., Reid, G.,
Schellens, J.H., Koomen, G.J. and Schinkel, A.H. (2002). Potent and specific inhibition of